Compare KD & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | GRFS |
|---|---|---|
| Founded | 2020 | 1940 |
| Country | United States | Spain |
| Employees | 80000 | 25247 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 5.8B |
| IPO Year | 2021 | N/A |
| Metric | KD | GRFS |
|---|---|---|
| Price | $12.75 | $8.03 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $35.25 | $10.15 |
| AVG Volume (30 Days) | ★ 5.2M | 647.4K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.77% |
| EPS Growth | ★ 170.95 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $15,057,000,000.00 | N/A |
| Revenue This Year | $3.96 | $5.33 |
| Revenue Next Year | $0.41 | $6.50 |
| P/E Ratio | ★ $16.44 | $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.10 | $6.19 |
| 52 Week High | $43.74 | $11.14 |
| Indicator | KD | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 36.01 | 30.37 |
| Support Level | $11.34 | $7.64 |
| Resistance Level | $13.93 | $9.11 |
| Average True Range (ATR) | 0.53 | 0.30 |
| MACD | 0.52 | -0.11 |
| Stochastic Oscillator | 60.64 | 4.38 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.